Saturday, October 3, 2026

EUR/CHF Over 2% Down In The Last 10 Sessions

EUR/CHF Over 2% Down In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 2.22% for the last 10 sessions. At 23:06 EST on Thursday, 6 June, EUR/CHF (EURCHF) is $0.97.

EUR/CHF's yearly highs and lows, it's 7.409% up from its 52-week low and 2.326% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Wednesday, 5 June, "Heading into the key central bank event and US macro data risks, Wednesday's US economic docket, featuring the ADP report and ISM Services PMI,might produce short-term opportunities around the EUR/USD pair.", "The EUR/USD pair builds on the overnight bounce from the 1.0860-1.0855 region and ticks higher during the Asian session on Wednesday amid subdued US Dollar (USD) price action. "
  • Eur/usd holds positive ground above 1.0850 ahead of ECB rate decision. According to FXStreet on Thursday, 6 June, "The EUR/USD pair gains ground around 1.0875 despite the recovery of the US Dollar (USD) during the early Asian session on Thursday. "
  • According to FXStreet on Thursday, 6 June, "ECB President Christine Lagarde's non-commital stance on the timing of the next rate cut could add extra legs to the EUR/USD recovery, as it would imply that the Bank could maintain rates higher for longer amid the persistence of inflation.", "On the other hand, if Lagarde dismisses concerns about sticky inflation, it could be read as a bit dovish by market participants, eventually rendering negative for the EUR/USD pair."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com